HIYASTA Market Drug Insight

“HIYASTA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about HIYASTA for Peripheral T-cell lymphoma (PTCL) in Japan. A detailed picture of the HIYASTA for Peripheral T-cell lymphoma (PTCL) in Japan for the study period 2019–2032 is provided in this report along with a detailed description of the HIYASTA for Peripheral T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HIYASTA market forecast, analysis for Peripheral T-cell lymphoma in Japan, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Peripheral T-cell lymphoma.

Drug Summary

HIYASTA, also known as HBI-8000, is an epigenetic immunomodulator with several approved indications, including monotherapy for two subtypes of T-cell non-Hodgkin’s lymphoma, i.e., relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) and relapsed or refractory PTCL in Japan. At the same time, HUYABIO International is conducting an overseas multinational Phase III clinical study of HIYASTA in combination with nivolumab in patients with untreated metastatic or unresectable malignant melanoma. HIYASTA is an oral agent which targets Class I histone deacetylases (HDAC), causing cell cycle arrest and tumor cell death as the mechanism underlying its single-agent activity against lymphoma.

The company was the first to leverage the Tripartite Agreement between China, Japan, and South Korea to use Chinese clinical data for a path for accelerated development of this drug in lymphoma.

Dosage and administration

40 mg of HIYASTA should be administered orally after a meal twice a week at 3- or 4-day intervals.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the HIYASTA description, mechanism of action, dosage and administration, research and development activities in Peripheral T-cell lymphoma (PTCL).
• Elaborated details on HIYASTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HIYASTA research and development activity in Peripheral T-cell lymphoma in detail across Japan.
• The report also covers the patents information with expiry timeline around HIYASTA.
• The report contains forecasted sales of HIYASTA for Peripheral T-cell lymphoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Peripheral T-cell lymphoma.
• The report also features the SWOT analysis with analyst views for HIYASTA in Peripheral T-cell lymphoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HIYASTA Analytical Perspective by DelveInsight

In-depth HIYASTA Market Assessment

This report provides a detailed market assessment of HIYASTA in Peripheral T-cell lymphoma (PTCL) in Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

HIYASTA Clinical Assessment

The report provides the clinical trials information of HIYASTA in Peripheral T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Peripheral T-cell lymphoma (PTCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HIYASTA dominance.
• Other emerging products for Peripheral T-cell lymphoma are expected to give tough market competition to HIYASTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HIYASTA in Peripheral T-cell lymphoma.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HIYASTA in Peripheral T-cell lymphoma.

Key Questions

• What is the product type, route of administration and mechanism of action of HIYASTA?
• What is the clinical trial status of the study related to HIYASTA in Peripheral T-cell lymphoma (PTCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HIYASTA development?
• What are the key designations that have been granted to HIYASTA for Peripheral T-cell lymphoma?
• What is the forecasted market scenario of HIYASTA for Peripheral T-cell lymphoma?
• What are the forecasted sales of HIYASTA in Japan? 
• What are the other emerging products available in Peripheral T-cell lymphoma and how are they giving competition to HIYASTA for Peripheral T-cell lymphoma?
•  
• Which are the late-stage emerging therapies under development for the treatment of Peripheral T-cell lymphoma?